Merck has announced a second collaboration agreement in its Bioelectronics innovation field with Innervia Bioelectronics. The aim of the collaboration is to co-develop the next generation of graphene-based bioelectronic vagus nerve therapies targeting severe chronic diseases within the therapeutic areas addressed by Merck.
“We aim to accelerate developments in the emerging field of bioelectronics by boosting the novel modality of selective neurostimulation,” said Laura Matz, Chief Science and Technology Officer of Merck KGaA, Darmstadt, Germany. “Today’s agreement with Innervia Bioelectronics gives our company access to a unique technology that increases energy efficiency in neurostimulators and could therefore become a true enabler for digital personalized treatment of patients suffering from severe and chronic diseases such as inflammatory disorders.”
Both partners will closely collaborate over the next few years to actively drive this potential paradigm change in treating diseases with high unmet medical needs. With its bioelectronics research facilities, Merck KGaA, Darmstadt, Germany is well equipped and can build on its data science, clinical, regulatory, and quality expertise to bring novel devices to patients in the near future. Innervia will add its technical expertise in the development of graphene interfaces, device development, and signal processing for clinical applications. Initial work will focus on inflammatory, metabolic, and endocrine disorders, using the promising capabilities of graphene for miniaturization, precision, and high modulation efficiency in the vagus nerve.
“Bioelectronic devices have the capability to directly communicate with the nervous system. Recording nerve signals and combining them with other accessible physiological datasets will lead to a better understanding of disease conditions and enable personalized treatment regimens,” said Robert Spoelgen, Head of Bioelectronics, Innovation Center of Merck KGaA, Darmstadt, Germany. “We are convinced that bioelectronic devices will play a significant role in the future therapeutic landscape.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!